Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24387685 | 0.85 | HTT (0.53) | KDM4ELMNAHTTNPSR1MAPT | |
| SCHEMBL8138982 | 0.84 | L3MBTL1 (0.46) | CYP1A2KDM4ANPSR1MAPTL3MBTL1 | |
| SCHEMBL411489 | 0.81 | CACNA1H (0.42) | CYP1A2KDM4ELMNAHTTKDM4A | |
| SCHEMBL5987499 | 0.81 | HTT (0.38) | CYP1A2KDM4ELMNAHTTKDM4A | |
| SCHEMBL5987962 | 0.80 | CYP1A2 (0.39) | CYP1A2KDM4ELMNAHTTKDM4A | |
| SCHEMBL7984088 | 0.79 | HTT (0.39) | CYP1A2KDM4ELMNAHTTKDM4A | |
| SCHEMBL14679174 | 0.79 | MAPT (0.66) | MAPTSMN1; SMN2 | |
| SCHEMBL3510594 | 0.79 | KCNJ1 (0.43) | KCNJ1LMNAMAPTCYP2C9CYP2C19 | |
| SCHEMBL425286 | 0.77 | ACACB (0.45) | KCNJ1NPSR1MAPTCYP2C9CYP2C19 | |
| SCHEMBL16375378 | 0.77 | MAPT (0.52) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357218-A1 | N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF | HANGZHOU WESTAN PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2023-11-09 | — | — | US | disclosed |
| CN-113004252-B | Aryl imidazole derivative and application thereof | 江苏先声药业有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-110099901-B | Pyrazolo [3,4-b ] pyridines and imidazo [1,5-b ] pyridazines as PDE1 inhibitors | H.隆德贝克有限公司 | 2023-01-03 | — | — | CN | disclosed |
| EP-3083619-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3558988-B1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H LUNDBECK AS (DK) | 2021-07-07 | — | — | EP | disclosed |
| US-10689379-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-06-23 | — | — | US | disclosed |
| US-20190352302-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-11-21 | — | — | US | disclosed |
| US-10351561-B2 | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2019-07-16 | — | — | US | disclosed |
| US-20180179200-A1 | PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-06-28 | — | — | US | disclosed |
| US-20180179200-A1 | PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-06-28 | — | — | US | disclosed |
| WO-2018115067-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-06-28 | — | — | WO | disclosed |
| US-8338599-B2 | Compounds having a potentiating effect on the activity of ethionamide and uses thereof | INSTITUT PASTEUR DE LILLE (FR) | 2012-12-25 | — | — | US | disclosed |
| WO-2012054510-A1 | OXADIAZOLE COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | INSTITUT PASTEUR DE LILLE (FR) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136823-A1 | COMPOUNDS HAVING A POTENTIATING EFFECT ON THE ACTIVITY OF ETHIONAMIDE AND USES THEREOF | EPX, PGLS, ENPEP | KCNJ1 3272/4885CYP1A2 568/4885KDM4E 391/4885 |
| US-20230357218-A1 | N-FORMAMIDOPYRAZOLINE DERIVATIVE AS P2X3 RECEPTOR ANTAGONIST AND USE THEREOF | P2RX3, P2RX4, P2RX7 | KCNJ1 80/4885CYP1A2 1694/4885KDM4E 4662/4885 |
| US-20190352302-A1 | PYRAZOLO[3,4-B]PYRIDINES AND IMIDAZO[1,5-B]PYRIDAZINES AS PDE1 INHIBITORS | PDE5A, PDE12, PDE3A | KCNJ1 1477/4885CYP1A2 102/4885KDM4E 1115/4885 |
| US-10689379-B2 | Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors | PDE5A, PDE12, PDE3A | KCNJ1 1477/4885CYP1A2 102/4885KDM4E 1115/4885 |
| US-10351561-B2 | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as PDE1 inhibitors | PDE5A, PDE12, PDE3A | KCNJ1 1477/4885CYP1A2 102/4885KDM4E 1115/4885 |
| US-20180179200-A1 | PYRAZOLO[3,4-b]PYRIDINES AND IMIDAZO[1,5-b]PYRIDAZINES AS PDE1 INHIBITORS | PDE5A, PDE12, PDE3A | KCNJ1 1477/4885CYP1A2 102/4885KDM4E 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.